Loading stock data…
Grifols (GRFS)
$7.33-0.06 (-0.81%)
After Hours$7.35+0.02 (+0.27%)· Last close Jun 29
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Grifols, S.A. in the Healthcare sector is trading at $7.33 with a market capitalization of $5.2B. Wall Street consensus targets $10.87 (2 analysts), implying a +48.2% move over the next 12 months. The stock is currently near its 52-week low of $7.08, remaining 15.7% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +48.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $1.70B↓ | $1.98B↑ | $1.89B↑ | $1.79B↓ | $1.98B |
| Gross Profit | $620.00M↓ | $686.84M↓ | $743.79M↑ | $695.00M↓ | $766.49M |
| Operating Income | $249.00M↓ | $275.38M↓ | $349.54M↑ | $274.00M↓ | $382.01M |
| Net Income | $73.00M↓ | $98.25M↓ | $117.06M↑ | $60.00M↓ | $68.97M |
Peer Comparison
JNJUNHPFE
Fundamentals
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.17B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.38%
Volume
Today's trading volume
511,017
Recent News
Grifols (GRFS) Launches FESILTY in the U.S. for Congenital Fibrinogen Deficiency Treatment
Grifols (NASDAQ:GRFS) is one of the top value stocks to buy under $10. On June 15, Grifols launched FESILTY in the US for treating acute bleeding in pediatric and adult patients with congenital fibrinogen deficiency/CFD, excluding dysfibrinogenemia. This highly purified human-derived fibrinogen concentrate provides a precise, targeted treatment for a rare genetic condition where insufficient […]
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
European equities traded in the US as American depositary receipts were trending higher late Tuesday
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
European equities traded in the US as American depositary receipts kicked off the week higher late M
Grifols, S.A. (GRFS) Sees Strong Biopharma Growth Led by Gamunex and Yimmugo
We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Grifols, S.A. (NASDAQ:GRFS) is among the most undervalued stocks. TheFly reported on May 12 that Deutsche Bank reduced its price target on GRFS from €11 to €10 while reaffirming a Hold rating on the stock. Earlier on May 7, Grifols, […]
European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday
European equities traded in the US as American depositary receipts were trending slightly lower late